An even dozen new medicines received positive opinions following CHMP’s September meeting, and can therefore expect forthcoming approval from the European Commission.
Among them is Frehemgo from Denmark’s Novo Nordisk, a treatment for haemophilia A developed to provide long‑acting prophylaxis with multiple dosing intervals – once monthly, every two weeks or once weekly.
BREAKING